Abiomed
Abiomed Receives 510(k) Clearance from FDA for Impella 2.5 Device  more

Acura Pharmaceuticals
Clinical results report on Acurox reported by BioCentury Part II (pdf)  more

Acura Pharmaceuticals' double blind, placebo-controlled Phase III trial shows Acurox met primary endpoint of significant difference in pain intensity vs placebo (pdf)  more

Acura Pharmaceuticals, Inc. Announces Notice of Issuance for Patent  more

BioForm Medical
Radiesse^® Dermal Filler Featured Prominently in Journal of Dermatologic Surgery Special Issue on Fillers  more

Radiesse^® Provides Greater Patient Satisfaction Than Either Juvederm or Perlane  more

BioForm Announces Financial Results for Quarter Ended September 30, 2007, First Quarter of Fiscal 2008  more

BioForm Strengthens Management Team with Three Leading Industry Executives  more

Bledsoe
Bledsoe Announces Partnership to Drive Growth (pdf) more

Ception Therapeutics
Ception Therapeutics Initiates Phase II/III Clinical Trial for its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children more

Ception Closes Year's 2nd Largest Biopharm Round (pdf) more

Ception Therapeutics Raises $63M in Series C Financing (pdf) more

Chroma Therapeutics
Chroma Announces Positive Phase I Efficacy Data For Novel Cancer Therapy CHR-2797( pdf) more

Elusys
Elusys' Anthim Dramatically Improves Survival Of Animals Treated After Active Anthrax Infection  more

Elusys Announces Collaborative Research and License Agreement with Pfizer (pdf)  more

Elusys and US Army Extend Biodefense Collaboration (pdf)  more

EUSA Pharma
Strategies of a Specialty Company: EUSA Pharma CEO Bryan Morton's Interview on PharmaVentures  view video

EUSA Pharma to Acquire US Specialty Oncology Company Cytogen   more

EUSA: Powering to be the Next Shire?   more

EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to Glaxosmithkline for up to $44 Million Plus Royalties  more

EUSA Pharma Announces $30 Million Debt Facilty  more

EUSA Pharma Acquires Assets of Innocoll, Inc. (pdf)  more

Healthcare Brands International
Healthcare Brands International Announces Acquisition of Antula Holdings AB more

Horizon Therapeutics
Horizon Therapeutics Names Timothy P Walbert as President and CEO  more

Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501  more

Horizon Therapeutics Completes $30M Equity Financing  more

InSound Medical
Raves (Yes, It's True) for New Hearing Aid  more

Iomai
Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation  more

Iomai Wins Department of Defense Grant to Develop a Stable, Patch-based Anthrax Vaccine more

Merck to Test Iomai Patch for Boosting Vaccine Immunity  more

Iomai Awarded Government Contract, Totaling $128 Million, to Develop Dose-Sparing Patch for Use in an Influenza Pandemic  more

LifeCell
KCI to Acquire LifeCell for $1.7B in Cash, Creating a Global Medical Technology Leader  more

Light Sciences Oncology
Light Sciences Oncology, Led by CEO on the Go, Prepares for Its Big Day   more

Revance Therapeutics
Revance Announces Series C Expansion more

Medicis and Revance Announce Strategic Collaboration more

StrataGent
StrataGent Life Sciences, Inc. Closes $16M Series B Financing  more

Symphogen
Symphogen Raises Equity in Genentech Collab Deal  more

Symphogen Issued Patent Covering Symplex™ Technology for Antibody Discovery  more

Symphogen to Present Positive Preclinical Data on Sym003 Program for RSV Infection  more

Xanodyne Pharmaceuticals
Xanodyne Achieves Positive Efficacy Results in Pivotal Phase 3 Studies of Proprietary Modified Release Oral Tranexamic Acid Product Candidate for Heavy Menstrual Bleeding (pdf)  more

Xanodyne Receives Approvable Letter from the US Food and Drug Administration for ZIPSOR^TM (diclofenac potassium) Capsules (pdf)  more

PORTFOLIO COMPANIES NEWS